Back to Results
First PageMeta Content
Glycoproteins / Eli Lilly and Company / ImClone Systems / Immunology / Biologic / Antibody / Antigen / Symphogen / Immune system / Biology / Biotechnology


Zymeworks Inc. Announces Strategic Collaboration with Lilly Subsidiary ImClone Systems to Develop Bi-specific Antibodies Using Zymeworks’ Azymetric™ Platform Vancouver, Canada (January 9, 2014) – Zymeworks Inc. tod
Add to Reading List

Document Date: 2014-01-09 09:19:28

Open Document

File Size: 300,78 KB

Share Result on Facebook

City

Vancouver / /

Company

IgG / ImClone Systems / Zymeworks Inc. / Eli Lilly and Company / Lilly Subsidiary ImClone Systems / /

Country

Canada / /

Event

Business Partnership / /

IndustryTerm

treatment of oncology / autoimmunity and inflammatory diseases / protein engineering technology / /

MedicalCondition

tumor / cancer / inflammatory diseases / /

Person

Ali Tehrani / /

Position

President and CEO / /

Product

ZymeCAD / /

Technology

protein engineering technology / Antibodies / /

URL

www.zymeworks.com / /

SocialTag